Hemophilia B Pipeline Set for Transformational Breakthroughs by 2026 with 20+ Therapies and Next-Generation Gene Editing Advances Led by Biocad, Regeneron, and Be Biopharma | DelveInsight

Hemophilia B Pipeline

The Hemophilia B therapeutic landscape is entering a new era of innovation, driven by rapid advancements in gene therapy, genome editing technologies, and next-generation biologics. A growing number of biopharmaceutical companies, including Biocad, Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, ISU ABXIS, and others, are actively redefining treatment paradigms through robust research and development efforts.

DelveInsight’s latest report, “Hemophilia B Pipeline Insight, 2026,” provides a comprehensive evaluation of more than 15 leading companies and over 20 pipeline therapies shaping the future of Hemophilia B treatment. The report delivers an in-depth analysis of pipeline drug profiles across clinical and nonclinical stages, along with a detailed therapeutic assessment based on product type, stage of development, route of administration, and molecule type. Additionally, it highlights inactive and discontinued programs, offering a holistic perspective of the evolving pipeline ecosystem.

Unlock the complete Hemophilia B pipeline landscape and strategic insights here: Hemophilia B Clinical Trial Analysis

Understanding Hemophilia B: A Genetic Disorder with Significant Clinical Burden

Hemophilia B, commonly referred to as Christmas disease, is a rare inherited bleeding disorder caused by mutations in the F9 gene. This genetic defect leads to a deficiency or dysfunction of coagulation factor IX, a critical protein required for normal blood clotting. The disease follows an X-linked recessive inheritance pattern, primarily affecting males, while females typically serve as carriers, although some may exhibit mild symptoms due to reduced factor IX levels.

In certain cases, Hemophilia B may also arise from spontaneous mutations during early development, further complicating its epidemiology. The severity of the condition is determined by the level of factor IX activity in the bloodstream, ranging from mild to severe forms, each associated with varying risks of spontaneous or trauma-induced bleeding episodes.

From a pathophysiological standpoint, Hemophilia B disrupts the intrinsic pathway of the coagulation cascade. Under normal conditions, vascular injury triggers platelet aggregation and subsequent activation of clotting factors, ultimately forming a stable fibrin clot. However, in Hemophilia B patients, insufficient factor IX impairs the activation of factor X, leading to inadequate fibrin formation and unstable clots. This results in prolonged bleeding, spontaneous hemorrhages, and potential complications such as joint damage, internal bleeding, and reduced quality of life.

Current treatment strategies primarily focus on replacing the deficient factor IX through recombinant or plasma-derived concentrates. These therapies are administered either on-demand during bleeding episodes or prophylactically to prevent complications. While effective, they often require lifelong administration and are associated with significant treatment burden and cost. Emerging therapies, particularly gene-based approaches, aim to provide long-term or potentially curative solutions.

Evolving Hemophilia B Pipeline Landscape: Innovation Driving Long-Term Solutions

The Hemophilia B pipeline is undergoing a significant transformation, fueled by breakthroughs in gene therapy, CRISPR-based genome editing, and cell-based therapies. Unlike traditional replacement therapies, these novel approaches aim to address the root cause of the disease by restoring endogenous factor IX production.

Explore how emerging technologies are revolutionizing Hemophilia B treatment: Hemophilia B Pipeline Outlook

The report highlights that more than 15 companies are actively engaged in developing innovative therapies, collectively advancing over 20 pipeline candidates across various stages of development. These therapies are designed to overcome the limitations of current treatments, including frequent dosing, variability in response, and high healthcare costs.

A strong emphasis is being placed on one-time gene therapies, extended half-life biologics, and precision medicine approaches that can significantly improve patient outcomes and reduce treatment burden. Additionally, advancements in vector engineering and delivery systems are enhancing the safety and efficacy of gene-based interventions.

Key Takeaways from the Hemophilia B Pipeline Report

• The Hemophilia B pipeline comprises over 20 active therapeutic candidates across early, mid, and late stages of development.
• Gene therapy and genome editing technologies are emerging as the most promising approaches for long-term disease management.
• Increasing focus on one-time curative treatments is expected to redefine standard of care.
• Strategic collaborations, licensing agreements, and mergers are accelerating innovation and clinical progress.
• Novel delivery platforms, including AAV vectors and lipid nanoparticles, are improving therapeutic precision.
• Cell-based therapies are gaining traction as a flexible and potentially re-dosable treatment option.
• Growing investment in rare disease research is driving pipeline expansion and technological advancements.
• In April 2026, Regeneron Pharmaceuticals announced results of a Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B
• In April 2026, Shanghai Xinzhi BioMed Co., Ltd. Announced results of a Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene (BBM-H901) Injection in Patients With Hemophilia B
• In March 2026, Pfizer Announced Results Of An Open-Label Study In Pediatric (
• In January 2026, CSL Behring announced results of a Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Chinese Subjects With Hemophilia B
• In March 2025, Sanofi announced that The US Food and Drug Administration (FDA) has approved QFITLIA (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with Hemophilia B A or B with or without factor VIII or IX inhibitors. The approval is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates (ABR) across Hemophilia B patients with or without inhibitors.
• In July 2025, The first patient has been dosed in the first-in-human Phase I/II clinical trial called BeCoMe-9 (NCT06611436) in the US This multi-center, open-label dose-escalation trial is designed to test the safety and preliminary efficacy of BE-101 in adults with moderately severe to severe Hemophilia B.
• In December 2025, CSL Behring reported long-term follow-up data for HEMGENIX demonstrating sustained factor IX expression and durable bleed control for over 4–5 years, reinforcing its transformative potential as a one-time gene therapy for Hemophilia B.

Stay ahead with detailed pipeline analytics and competitive intelligence: Hemophilia B Competitive Landscape

Hemophilia B Emerging Drugs: Advancing Toward Curative Therapies

ANB-002: Biocad

ANB-002 (arvenacogene sanparvovec) represents a groundbreaking gene therapy designed to provide long-term correction of Hemophilia B. Utilizing an AAV5 vector, the therapy delivers a functional copy of the factor IX gene directly to liver cells, enabling endogenous production of the protein. Administered as a single intravenous infusion, ANB-002 has the potential to significantly reduce or eliminate the need for regular factor replacement therapy. Currently in Phase III clinical trials, it stands among the most advanced candidates in the pipeline.

BE-101: Be Biopharma

BE-101 is a first-in-class autologous B cell medicine engineered to produce sustained levels of functional factor IX. By inserting the FIX gene into primary human B cells, this therapy offers a novel mechanism for continuous protein expression. Its re-dosable nature provides a significant advantage over traditional gene therapies, addressing concerns related to durability and long-term efficacy. The therapy is currently in Phase I/II clinical development.

REGV131-LNP1265: Regeneron Pharmaceuticals / Intellia Therapeutics

REGV131-LNP1265 is an innovative in vivo CRISPR/Cas9-based gene editing therapy designed to enable liver cells to produce functional factor IX. Delivered via lipid nanoparticles, this approach offers a non-viral alternative to traditional gene therapies. The therapy aims to provide a one-time, durable treatment, eliminating the need for frequent infusions. It is currently being evaluated in Phase I/II clinical trials.

Dive deeper into drug mechanisms, clinical data, and development strategies: Hemophilia B Clinical Trial and FDA Approval

Hemophilia B Pipeline Segmentation and Therapeutic Assessment

The report provides a detailed segmentation of pipeline therapies based on multiple parameters, offering a comprehensive understanding of the treatment landscape.

Hemophilia B Clinical Development Phases

• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

Hemophilia B Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Parenteral
• Intrathecal
• Topical
• Transdermal
• Intraocular
• Intra-articular

Hemophilia B Molecule Types

• Small molecules
• Peptides
• Oligonucleotides

Hemophilia B Product Types

• Monotherapy
• Combination therapy
• Mono/Combination approaches

These diverse therapeutic strategies reflect the complexity of Hemophilia B and the need for innovative, patient-centric solutions.

Hemophilia B Clinical Trial and Development Activities

The Hemophilia B pipeline is characterized by increasing clinical trial activity and a growing number of strategic partnerships. Companies are actively collaborating with academic institutions and research organizations to accelerate drug development and bring novel therapies to market.

Key players such as Biocad, Regeneron Pharmaceuticals, and Be Biopharma are leading the innovation wave, while emerging biotech firms are exploring disruptive technologies such as CRISPR gene editing and cell-based therapies. Licensing agreements, mergers, and acquisitions are further strengthening the competitive landscape and enabling faster clinical progression.

Hemophilia B Market Drivers, Challenges, and Future Outlook

The growth of the Hemophilia B pipeline is driven by several key factors, including increasing awareness of rare genetic disorders, advancements in biotechnology, and rising demand for long-term treatment solutions. The shift toward precision medicine and personalized therapies is further fueling innovation in this space.

However, challenges remain. High development costs, regulatory complexities, and concerns regarding long-term safety and durability of gene therapies continue to pose hurdles. Additionally, variability in patient response and limited accessibility in certain regions may impact adoption rates.

Despite these challenges, the future outlook for Hemophilia B remains highly promising. The integration of advanced technologies such as artificial intelligence, biomarker discovery, and next-generation delivery systems is expected to revolutionize treatment approaches. As more therapies progress through clinical trials, the possibility of achieving functional cures is becoming increasingly realistic.

Access exclusive insights into clinical trials, collaborations, and pipeline dynamics: Hemophilia B Companies and Medication

Scope of the Hemophilia B Pipeline Report

• Coverage: Global
• Key Hemophilia B Companies: Biocad, ISU ABXIS, Gyre Therapeutics, Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, Suzhou Alphamab, Equilibra Bioscience, UBI Pharma, Staidson Biopharmaceuticals, and others
• Key Hemophilia B Therapies: ANB-002, ISU304, BE-101, REGV131-LNP1265, KN057, SR604, UB-854, STSP-0601
• Therapeutic Assessment: Product type, clinical stage, route of administration, molecule type

Table of Contents

1. Introduction
2. Executive Summary
3. Hemophilia B Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

Key Questions Answered

• How many companies are actively developing Hemophilia B therapies?
• What is the distribution of pipeline drugs across clinical stages?
• Which novel technologies are shaping the future of treatment?
• What are the latest clinical trial developments and outcomes?
• How are collaborations and partnerships influencing innovation?
• What are the key unmet needs and future opportunities in the market?

Final Perspective

The Hemophilia B pipeline is poised for significant transformation, driven by cutting-edge innovations and a strong commitment to addressing unmet medical needs. As next-generation therapies continue to advance, the possibility of achieving long-term remission—or even a cure—is becoming increasingly tangible. With continued investment, collaboration, and technological progress, the future of Hemophilia B treatment looks more promising than ever.

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting